{
  "study_id": "KEYNOTE-024",
  "study_title": "Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer",
  "table_name": "Table 1",
  "table_title": "Baseline Demographic and Disease Characteristics of Patients in the Intention-to-Treat Population.",
  "footnotes": [
    "The intention-to-treat population included all patients who underwent randomization. There were no significant differences between treatment groups.",
    "Eastern Cooperative Oncology Group (ECOG) performance-status scores range from 0 to 5, with 0 indicating no symptoms and higher scores indicating increasing disability. One patient (0.6%), who was in the pembrolizumab group, had an ECOG performance-status score of 2."
  ],
  "groups": [
    {
      "name": "Pembrolizumab Group",
      "n": 154,
      "type": "Intervention"
    },
    {
      "name": "Chemotherapy Group",
      "n": 151,
      "type": "Control"
    }
  ],
  "characteristics": [
    {
      "original_label": "Age — yr",
      "standardized_name": "Age",
      "unit": "years",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Pembrolizumab Group",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Chemotherapy Group",
          "data_type": "header",
          "raw_string": ""
        }
      ]
    },
    {
      "original_label": "Median",
      "standardized_name": "Age",
      "unit": "years",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Age",
      "group_data": [
        {
          "group_name": "Pembrolizumab Group",
          "data_type": "numeric_single",
          "value": 64.5,
          "raw_string": "64.5",
          "n_for_value": 154
        },
        {
          "group_name": "Chemotherapy Group",
          "data_type": "numeric_single",
          "value": 66.0,
          "raw_string": "66.0",
          "n_for_value": 151
        }
      ]
    },
    {
      "original_label": "Range",
      "standardized_name": "Age range",
      "unit": "years",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Age",
      "group_data": [
        {
          "group_name": "Pembrolizumab Group",
          "data_type": "numeric_mean_range",
          "range_min": 33.0,
          "range_max": 90.0,
          "raw_string": "33–90",
          "n_for_value": 154
        },
        {
          "group_name": "Chemotherapy Group",
          "data_type": "numeric_mean_range",
          "range_min": 38.0,
          "range_max": 85.0,
          "raw_string": "38–85",
          "n_for_value": 151
        }
      ]
    },
    {
      "original_label": "Male sex — no. (%)",
      "standardized_name": "Sex",
      "category": "Male",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Pembrolizumab Group",
          "data_type": "categorical_count_percentage",
          "count": 92.0,
          "percentage": 59.7,
          "raw_string": "92 (59.7)",
          "n_for_value": 154
        },
        {
          "group_name": "Chemotherapy Group",
          "data_type": "categorical_count_percentage",
          "count": 95.0,
          "percentage": 62.9,
          "raw_string": "95 (62.9)",
          "n_for_value": 151
        }
      ]
    },
    {
      "original_label": "Region of enrollment — no. (%)",
      "standardized_name": "Region of enrollment",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Pembrolizumab Group",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Chemotherapy Group",
          "data_type": "header",
          "raw_string": ""
        }
      ]
    },
    {
      "original_label": "East Asia",
      "standardized_name": "Region of enrollment",
      "category": "East Asia",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Region of enrollment",
      "group_data": [
        {
          "group_name": "Pembrolizumab Group",
          "data_type": "categorical_count_percentage",
          "count": 21.0,
          "percentage": 13.6,
          "raw_string": "21 (13.6)",
          "n_for_value": 154
        },
        {
          "group_name": "Chemotherapy Group",
          "data_type": "categorical_count_percentage",
          "count": 19.0,
          "percentage": 12.6,
          "raw_string": "19 (12.6)",
          "n_for_value": 151
        }
      ]
    },
    {
      "original_label": "Non–East Asia",
      "standardized_name": "Region of enrollment",
      "category": "Non-East Asia",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Region of enrollment",
      "group_data": [
        {
          "group_name": "Pembrolizumab Group",
          "data_type": "categorical_count_percentage",
          "count": 133.0,
          "percentage": 86.4,
          "raw_string": "133 (86.4)",
          "n_for_value": 154
        },
        {
          "group_name": "Chemotherapy Group",
          "data_type": "categorical_count_percentage",
          "count": 132.0,
          "percentage": 87.4,
          "raw_string": "132 (87.4)",
          "n_for_value": 151
        }
      ]
    },
    {
      "original_label": "ECOG performance-status score — no. (%)",
      "standardized_name": "ECOG performance status score",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Pembrolizumab Group",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Chemotherapy Group",
          "data_type": "header",
          "raw_string": ""
        }
      ]
    },
    {
      "original_label": "0",
      "standardized_name": "ECOG performance status score",
      "category": "0",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "ECOG performance status score",
      "group_data": [
        {
          "group_name": "Pembrolizumab Group",
          "data_type": "categorical_count_percentage",
          "count": 54.0,
          "percentage": 35.1,
          "raw_string": "54 (35.1)",
          "n_for_value": 154
        },
        {
          "group_name": "Chemotherapy Group",
          "data_type": "categorical_count_percentage",
          "count": 53.0,
          "percentage": 35.1,
          "raw_string": "53 (35.1)",
          "n_for_value": 151
        }
      ]
    },
    {
      "original_label": "1",
      "standardized_name": "ECOG performance status score",
      "category": "1",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "ECOG performance status score",
      "group_data": [
        {
          "group_name": "Pembrolizumab Group",
          "data_type": "categorical_count_percentage",
          "count": 99.0,
          "percentage": 64.3,
          "raw_string": "99 (64.3)",
          "notes": "One patient (0.6%) had an ECOG performance-status score of 2.",
          "n_for_value": 154
        },
        {
          "group_name": "Chemotherapy Group",
          "data_type": "categorical_count_percentage",
          "count": 98.0,
          "percentage": 64.9,
          "raw_string": "98 (64.9)",
          "n_for_value": 151
        }
      ]
    },
    {
      "original_label": "Smoking status — no. (%)",
      "standardized_name": "Smoking status",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Pembrolizumab Group",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Chemotherapy Group",
          "data_type": "header",
          "raw_string": ""
        }
      ]
    },
    {
      "original_label": "Current",
      "standardized_name": "Smoking status",
      "category": "Current",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Smoking status",
      "group_data": [
        {
          "group_name": "Pembrolizumab Group",
          "data_type": "categorical_count_percentage",
          "count": 34.0,
          "percentage": 22.1,
          "raw_string": "34 (22.1)",
          "n_for_value": 154
        },
        {
          "group_name": "Chemotherapy Group",
          "data_type": "categorical_count_percentage",
          "count": 31.0,
          "percentage": 20.5,
          "raw_string": "31 (20.5)",
          "n_for_value": 151
        }
      ]
    },
    {
      "original_label": "Former",
      "standardized_name": "Smoking status",
      "category": "Former",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Smoking status",
      "group_data": [
        {
          "group_name": "Pembrolizumab Group",
          "data_type": "categorical_count_percentage",
          "count": 115.0,
          "percentage": 74.7,
          "raw_string": "115 (74.7)",
          "n_for_value": 154
        },
        {
          "group_name": "Chemotherapy Group",
          "data_type": "categorical_count_percentage",
          "count": 101.0,
          "percentage": 66.9,
          "raw_string": "101 (66.9)",
          "n_for_value": 151
        }
      ]
    },
    {
      "original_label": "Never",
      "standardized_name": "Smoking status",
      "category": "Never",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Smoking status",
      "group_data": [
        {
          "group_name": "Pembrolizumab Group",
          "data_type": "categorical_count_percentage",
          "count": 5.0,
          "percentage": 3.2,
          "raw_string": "5 (3.2)",
          "n_for_value": 154
        },
        {
          "group_name": "Chemotherapy Group",
          "data_type": "categorical_count_percentage",
          "count": 19.0,
          "percentage": 12.6,
          "raw_string": "19 (12.6)",
          "n_for_value": 151
        }
      ]
    },
    {
      "original_label": "Histology — no. (%)",
      "standardized_name": "Histology",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Pembrolizumab Group",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Chemotherapy Group",
          "data_type": "header",
          "raw_string": ""
        }
      ]
    },
    {
      "original_label": "Squamous",
      "standardized_name": "Histology",
      "category": "Squamous",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Histology",
      "group_data": [
        {
          "group_name": "Pembrolizumab Group",
          "data_type": "categorical_count_percentage",
          "count": 29.0,
          "percentage": 18.8,
          "raw_string": "29 (18.8)",
          "n_for_value": 154
        },
        {
          "group_name": "Chemotherapy Group",
          "data_type": "categorical_count_percentage",
          "count": 27.0,
          "percentage": 17.9,
          "raw_string": "27 (17.9)",
          "n_for_value": 151
        }
      ]
    },
    {
      "original_label": "Nonsquamous",
      "standardized_name": "Histology",
      "category": "Nonsquamous",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Histology",
      "group_data": [
        {
          "group_name": "Pembrolizumab Group",
          "data_type": "categorical_count_percentage",
          "count": 125.0,
          "percentage": 81.2,
          "raw_string": "125 (81.2)",
          "n_for_value": 154
        },
        {
          "group_name": "Chemotherapy Group",
          "data_type": "categorical_count_percentage",
          "count": 124.0,
          "percentage": 82.1,
          "raw_string": "124 (82.1)",
          "n_for_value": 151
        }
      ]
    },
    {
      "original_label": "Brain metastases — no. (%)",
      "standardized_name": "Brain metastases at baseline",
      "category": "Yes",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Pembrolizumab Group",
          "data_type": "categorical_count_percentage",
          "count": 18.0,
          "percentage": 11.7,
          "raw_string": "18 (11.7)",
          "n_for_value": 154
        },
        {
          "group_name": "Chemotherapy Group",
          "data_type": "categorical_count_percentage",
          "count": 10.0,
          "percentage": 6.6,
          "raw_string": "10 (6.6)",
          "n_for_value": 151
        }
      ]
    },
    {
      "original_label": "Previous systemic neoadjuvant therapy — no. (%)",
      "standardized_name": "Previous systemic neoadjuvant therapy",
      "category": "Yes",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Pembrolizumab Group",
          "data_type": "categorical_count_percentage",
          "count": 3.0,
          "percentage": 1.9,
          "raw_string": "3 (1.9)",
          "n_for_value": 154
        },
        {
          "group_name": "Chemotherapy Group",
          "data_type": "categorical_count_percentage",
          "count": 1.0,
          "percentage": 0.7,
          "raw_string": "1 (0.7)",
          "n_for_value": 151
        }
      ]
    },
    {
      "original_label": "Previous systemic adjuvant therapy — no. (%)",
      "standardized_name": "Previous systemic adjuvant therapy",
      "category": "Yes",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Pembrolizumab Group",
          "data_type": "categorical_count_percentage",
          "count": 6.0,
          "percentage": 3.9,
          "raw_string": "6 (3.9)",
          "n_for_value": 154
        },
        {
          "group_name": "Chemotherapy Group",
          "data_type": "categorical_count_percentage",
          "count": 3.0,
          "percentage": 2.0,
          "raw_string": "3 (2.0)",
          "n_for_value": 151
        }
      ]
    }
  ]
}